The Oncolytic Adenovirus Delta-24-RGD in Combination with ONC201 Induces a Potent Antitumor Response in Pediatric High-grade and Diffuse Midline Glioma Models

Background: Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated.

Methods: The production of functional viruses was assessed by immunoblotting and replication assays. The antitumor effect was evaluated in a panel of human and murine pHGG and DMG cell lines. RNAseq, the seahorse stress test, mitochondrial DNA content, and γH2A.X immunofluorescence were used to perform mechanistic studies. Mouse models of both diseases were used to assess the efficacy of the combination in vivo. The tumor immune microenvironment was evaluated using flow cytometry, RNAseq, and multiplexed immunofluorescence staining.

Results: The Delta-24-RGD/ONC201 combination did not affect the virus replication capability in human pHGG and DMG models in vitro. Cytotoxicity analysis showed that the combination treatment was either synergistic or additive. Mechanistically, the combination treatment increased nuclear DNA damage and maintained the metabolic perturbation and mitochondrial damage caused by each agent alone. Delta-24-RGD/ONC201 cotreatment extended the overall survival of mice implanted with human and murine pHGG and DMG cells, independent of H3 mutation status and location. Finally, combination treatment in murine DMG models revealed a reshaping of the tumor microenvironment to a proinflammatory phenotype.

Conclusions: The Delta-24-RGD/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.

References

Kline C, van den Heuvel A, Allen J, Prabhu V, Dicker D, El-Deiry W . ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Sci Signal. 2016; 9(415):ra18. PMC: 4968406. DOI: 10.1126/scisignal.aac4374. View

Prabhu V, Talekar M, Lulla A, Kline C, Zhou L, Hall J . Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle. 2017; 17(4):468-478. PMC: 5927637. DOI: 10.1080/15384101.2017.1403689. View

Madhukar N, Khade P, Huang L, Gayvert K, Galletti G, Stogniew M . A Bayesian machine learning approach for drug target identification using diverse data types. Nat Commun. 2019; 10(1):5221. PMC: 6863850. DOI: 10.1038/s41467-019-12928-6. View

Karen K, Hearing P . Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection. J Virol. 2011; 85(9):4135-42. PMC: 3126275. DOI: 10.1128/JVI.02540-10. View

Halvorson K, Barton K, Schroeder K, Misuraca K, Hoeman C, Chung A . A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS One. 2015; 10(3):e0118926. PMC: 4352073. DOI: 10.1371/journal.pone.0118926. View

Horbinski C, Berger T, Packer R, Wen P . Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol. 2022; 18(9):515-529. DOI: 10.1038/s41582-022-00679-w. View

Kaufman H, Kohlhapp F, Zloza A . Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015; 14(9):642-62. PMC: 7097180. DOI: 10.1038/nrd4663. View

Di Cristofano F, Fong M, Huntington K, Carneiro B, Zhou L, El-Deiry W . Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis. Am J Cancer Res. 2023; 13(1):307-325. PMC: 9906082. View

Friedman G, Johnston J, Bag A, Bernstock J, Li R, Aban I . Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med. 2021; 384(17):1613-1622. PMC: 8284840. DOI: 10.1056/NEJMoa2024947. View

10.

Wagner J, Kline C, Zhou L, Campbell K, Macfarlane A, Olszanski A . Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018; 128(6):2325-2338. PMC: 5983321. DOI: 10.1172/JCI96711. View

11.

Fueyo J, Alemany R, Gomez-Manzano C, Fuller G, Khan A, Conrad C . Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003; 95(9):652-60. DOI: 10.1093/jnci/95.9.652. View

12.

Pescini Gobert R, Joubert L, Curchod M, Salvat C, Foucault I, Jorand-Lebrun C . Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits. Mol Cell Biol. 2009; 29(6):1538-53. PMC: 2648232. DOI: 10.1128/MCB.01375-08. View

13.

Stein M, Bertino J, Kaufman H, Mayer T, Moss R, Silk A . First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017; 23(15):4163-4169. PMC: 7595575. DOI: 10.1158/1078-0432.CCR-16-2658. View

14.

Blair G, Dixon S, Griffiths S, Zajdel M . Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res. 1989; 14(4):339-46. DOI: 10.1016/0168-1702(89)90026-9. View

15.

Hoffman L, Veldhuijzen van Zanten S, Colditz N, Baugh J, Chaney B, Hoffmann M . Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018; 36(19):1963-1972. PMC: 6075859. DOI: 10.1200/JCO.2017.75.9308. View

16.

MacDonald T, Aguilera D, Kramm C . Treatment of high-grade glioma in children and adolescents. Neuro Oncol. 2011; 13(10):1049-58. PMC: 3177659. DOI: 10.1093/neuonc/nor092. View

17.

Miao Y, Xia M, Luo M, Luo T, Yang M, Guo A . ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction. Bioinformatics. 2021; 38(3):785-791. DOI: 10.1093/bioinformatics/btab711. View

18.

Dunkel I, Doz F, Foreman N, Hargrave D, Lassaletta A, Andre N . Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023; 25(8):1530-1545. PMC: 10398811. DOI: 10.1093/neuonc/noad031. View

19.

Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor K . Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017; 32(4):520-537.e5. PMC: 5637314. DOI: 10.1016/j.ccell.2017.08.017. View

20.

Garcia-Moure M, Gonzalez-Huarriz M, Labiano S, Guruceaga E, Bandres E, Zalacain M . Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET. Clin Cancer Res. 2020; 27(6):1807-1820. PMC: 7617079. DOI: 10.1158/1078-0432.CCR-20-3313. View